Health care stocks climbed late Monday afternoon with the NYSE Health Care Index up 0.5% and the Health Care Select Sector SPDR Fund (XLV) rising 0.8%.
The iShares Biotechnology ETF (IBB) climbed 1.3%.
In corporate news, Unity Biotechnology (UBX) shares fell 28%. The company's UBX1325, the diabetic macular edema treatment for patients with poor vision, didn't achieve statistical non-inferiority at the primary analysis endpoint in a phase 2b trial.
TransCode Therapeutics (RNAZ) shares dropped 38%. The company agreed to sell shares to raise $10 million.
23andMe (ME) filed for Chapter 11 bankruptcy protection to help facilitate a potential sale, while Anne Wojcicki resigned as chief executive officer, less than a month after she attempted to buy the genetic testing firm. 23andMe shares tumbled 59%.
Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. Novo shares shed 2%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。